Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: AbbVie's eight-week HCV regimen leads to 98% SVR12

    AbbVie Inc. (NYSE:ABBV) and partner Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) said an eight-week regimen of Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir led to an SVR12 in 160 (98%) of 163 evaluable…

    Published on 9/23/2016
  • CLINICAL NEWS: J&J six-week combo cures all HCV patients in Phase II cohort

    All 20 patients receiving a six-week course of a triple-combination therapy from Johnson & Johnson (NYSE:JNJ) to treat HCV genotype 1 infection achieved an SVR12 in a Phase II study, according to J&J's partners …

    Published on 9/23/2016
  • CLINICAL NEWS: Lundbeck's idalopirdine fails in Phase III AD trial

    H. Lundbeck A/S (CSE:LUN) said idalopirdine (Lu AE58054) missed the primary and secondary endpoints in the Phase III STARSHINE study to treat mild to moderate Alzheimer's disease. Idalopirdine is a serotonin (5-HT6) …

    Published on 9/22/2016
  • CLINICAL NEWS: Teva's SD-809 passes latest tardive dyskinesia test

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said two doses of SD-809 deutetrabenazine met the primary endpoint in the Phase III AIM-TD study to treat moderate to severe tardive dyskinesia. The company intends to …

    Published on 9/22/2016
  • CLINICAL NEWS: Adamas PD candidate nears NDA

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) said ADS-5102 met the primary endpoint in the Phase III EASE LID 3 study to treat levodopa-induced dyskinesia (LID) in Parkinson's disease patients. Compared with placebo, the …

    Published on 9/21/2016
  • CLINICAL NEWS: Gilead ends ulcerative colitis study due to futility

    Gilead Sciences Inc. (NASDAQ:GILD) said it is stopping a Phase II/III study of ulcerative colitis candidate GS-5745 based on an interim futility analysis that showed "insufficient evidence of a treatment benefit" in …

    Published on 9/21/2016
  • CLINICAL NEWS: Monkey with ASD traits used in 'phenotype first' model

    Researchers identified a Japanese macaque exhibiting autistic traits that could be useful in developing a better primate model for autism spectrum disorder. The findings were published Wednesday in the journal Science …

    Published on 9/21/2016
  • CLINICAL NEWS: Novartis EXPANDs on Phase III MS results

    In newly presented data, Novartis AG (NYSE:NVS; SIX:NOVN) said secondary progressive multiple sclerosis (SPMS) candidate siponimod (BAF312) reduced the risk of three-month confirmed disability progression by 21% …

    Published on 9/19/2016
  • CLINICAL NEWS: Teva HD candidate pridopidine heading for Phase III

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hopes to begin a Phase III program next year of pridopidine to treat Huntington's disease after seeing possible evidence of a disease-modifying effect in the exploratory …

    Published on 9/19/2016
  • CLINICAL NEWS: Vical's CMV vaccine misses in kidney transplant study

    Vical Inc. (NASDAQ:VICL) and partner Astellas Pharma Inc. (Tokyo:4503) said ASP0113 missed the primary endpoint in a Phase II study to prevent cytomegalovirus reactivation in kidney transplant patients receiving an …

    Published on 9/19/2016
  • CLINICAL NEWS: AZ diabetes combo passes Phase III test

    AstraZeneca plc (LSE:AZN; NYSE:AZN) said a combination of Bydureon exenatide plus Farxiga dapagliflozin met the primary endpoint in the Phase III DURATION-8 study to treat Type II diabetes. Patients receiving the …

    Published on 9/16/2016
  • CLINICAL NEWS: Biogen ties anti-LINGO miss to non-linear dose response

    Biogen Inc. (NASDAQ:BIIB) suggested a non-linear dose response to opicinumab (BIIB033) could have led to the compound's failure to meet the primary endpoint in the Phase II SYNERGY study to treat relapsing forms of …

    Published on 9/16/2016
  • CLINICAL NEWS: Aerie's ophthalmic combo passes first Phase III test

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI) jumped $13.47 (64%) to $34.60 in early after-hours trading Wednesday after its Roclatan netarsudil/latanoprost (PG324) met the primary endpoint in the Phase III Mercury 1 trial. …

    Published on 9/14/2016
  • CLINICAL NEWS: Applied Genetic slides after clinical updates

    Applied Genetic Technologies Corp. (NASDAQ:AGTC) fell $4.19 (32%) to $9 on Tuesday after it said enrollment was slower than expected in two Phase I/II studies of its ocular gene therapy candidates. One of the studies …

    Published on 9/13/2016
  • CLINICAL NEWS: Celgene reports Phase Ib Crohn's data

    Celgene Corp. (NASDAQ:CELG) said 12-week interim data showed that oral mongersen (GED-0301) led to endoscopic improvement and clinical response and remission in "a proportion of patients" across all treatment groups in …

    Published on 9/12/2016
  • CLINICAL NEWS: Geron falls on imetelstat update

    Geron Corp. (NASDAQ:GERN) sank $0.56 (20%) to $2.30 on Monday after reporting that partner Janssen Biotech Inc. will close the low-dose arm of the Phase II IMbark study of imetelstat (GRN163L) to treat myelofibrosis (MF…

    Published on 9/12/2016
  • CLINICAL NEWS: Optune survival readout boosts Novocure

    Novocure Ltd. (NASDAQ:NVCR) gained $0.53 to $8.62 on Monday after it said a long-term analysis of a Phase III study showed Optune (NovoTTF-100A) significantly improved survival after four years in patients with newly …

    Published on 9/12/2016
  • CLINICAL NEWS: U.K. researchers: Statin risks exaggerated

    In a review published Friday in The Lancet, U.K. researchers said claims about the side effects of statin therapy have been exaggerated, and expressed concern over reduced statin use to prevent cardiovascular events. …

    Published on 9/9/2016
  • CLINICAL NEWS: bluebird rises on LentiGlobin update

    bluebird bio Inc. (NASDAQ:BLUE) gained $4.70 to $57.51 on Thursday after starting the Phase III HGB-207 study of LentiGlobin BB305 gene therapy to treat beta-thalassemia. The company said HGB-207 will use LentiGlobin …

    Published on 9/8/2016
  • CLINICAL NEWS: GTx gains on Phase II breast cancer milestone

    GTx Inc. (NASDAQ:GTXI) added $0.14 (22%) to $0.77 on Thursday after it said a sufficient clinical benefit had been shown for the low-dose cohort of a Phase II trial of breast cancer candidate enobosarm (GTx-024) to …

    Published on 9/8/2016
  • CLINICAL NEWS: Retrophin jumps on Phase II FSGS data

    Retrophin Inc. (NASDAQ:RTRX) rose $4.49 (28%) to $20.81 on Wednesday after it said combined data from the three cohorts of the Phase II DUET study showed sparsentan (RE-021) met the trial's primary endpoint to treat …

    Published on 9/7/2016
  • CLINICAL NEWS: Amgen moving omecamtiv mecarbil into Phase III

    Amgen Inc. (NASDAQ:AMGN) will advance omecamtiv mecarbil into Phase III testing to treat chronic heart failure (CHF), with a cardiovascular outcomes study of the cardiac myosin activator expected to start next quarter. …

    Published on 9/1/2016
  • CLINICAL NEWS: Nobel Laureate Tsien passes away

    Roger Tsien, a Nobel Laureate and professor of pharmacology, chemistry and biochemistry at the University of California San Diego School of Medicine, passed away last week according to a statement from UCSD. He was 64.…

    Published on 8/31/2016
  • CLINICAL NEWS: Takeda begins real-world MM study

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said began it enrolling multiple myeloma patients in its global observational INSIGHT-MM study, which aims to track patterns in disease presentation, patient characteristics, …

    Published on 8/31/2016
  • CLINICAL NEWS: CardioCell reports Phase IIa heart failure data

    Data presented at the European Society of Cardiology meeting in Rome showed that a single intravenous administration of ischemic-tolerant mesenchymal stem cells (itMSCs) from CardioCell LLC met the primary safety …

    Published on 8/30/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993